Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the Tigecycline In Vitro Surveillance in Taiwan study, 2006 to 2010.
The Tigecycline In Vitro Surveillance in Taiwan (TIST) study, a nationwide, prospective surveillance during 2006 to 2010, collected a total of 7,793 clinical isolates, including methicillin-resistant Staphylococcus aureus (MRSA) (n = 1,834), penicillin-resistant Streptococcus pneumoniae (PRSP) (n = 423), vancomycin-resistant enterococci (VRE) (n = 219), extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (n = 1,141), ESBL-producing Klebsiella pneumoniae (n = 1,330), Acinetobacter baumannii (n = 1,645), and Stenotrophomonas maltophilia (n = 903), from different specimens from 20 different hospitals in Taiwan. MICs of tigecycline were determined following the criteria of the U.S. Food and Drug Administration (FDA) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST-2011). Among drug-resistant Gram-positive pathogens, all of the PRSP isolates were susceptible to tigecycline (MIC(90), 0.03 μg/ml), and only one MRSA isolate (MIC(90), 0.5 μg/ml) and three VRE isolates (MIC(90), 0.125 μg/ml) were nonsusceptible to tigecycline. Among the Gram-negative bacteria, the tigecycline susceptibility rates were 99.65% for ESBL-producing E. coli (MIC(90), 0.5 μg/ml) and 96.32% for ESBL-producing K. pneumoniae (MIC(90), 2 μg/ml) when interpreted by FDA criteria but were 98.7% and 85.8%, respectively, when interpreted by EUCAST-2011 criteria. The susceptibility rate for A. baumannii (MIC(90), 4 μg/ml) decreased from 80.9% in 2006 to 55.3% in 2009 but increased to 73.4% in 2010. A bimodal MIC distribution was found among carbapenem-susceptible A. baumannii isolates, and a unimodal MIC distribution was found among carbapenem-nonsusceptible A. baumannii isolates. In Taiwan, tigecycline continues to have excellent in vitro activity against several major clinically important drug-resistant bacteria, with the exception of A. baumannii.
Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, and Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Yen-Hsu
YH
Chen
Po-Liang
PL
Lu
Cheng-Hua
CH
Huang
Chun-Hsing
CH
Liao
Chin-Te
CT
Lu
Yin-Ching
YC
Chuang
Shih-Ming
SM
Tsao
Yao-Shen
YS
Chen
Yung-Ching
YC
Liu
Wei-Yu
WY
Chen
Tsrang-Neng
TN
Jang
Hsiu-Chen
HC
Lin
Chih-Ming
CM
Chen
Zhi-Yuan
ZY
Shi
Sung-Ching
SC
Pan
Jia-Ling
JL
Yang
Hsiang-Chi
HC
Kung
Chun-Eng
CE
Liu
Yu-Jen
YJ
Cheng
Jien-Wei
JW
Liu
Wu
W
Sun
Lih-Shinn
LS
Wang
Wen-Chien
WC
Ko
Kwok-Woon
KW
Yu
Ping-Cherng
PC
Chiang
Ming-Hsun
MH
Lee
Chun-Ming
CM
Lee
Gwo-Jong
GJ
Hsu
Po-Ren
PR
Hsueh
D040981:Acinetobacter baumannii / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015780:Carbapenems / Q000494:pharmacology; D024881:Drug Resistance, Bacterial; D016984:Enterococcus faecium / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification; D004926:Escherichia coli / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D006094:Gram-Positive Bacteria / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D006801:Humans; D007711:Klebsiella pneumoniae / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification; D008137:Longitudinal Studies; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology; D013624:Taiwan; D000078304:Tigecycline; D014640:Vancomycin / Q000494:pharmacology; D001618:beta-Lactamases / Q000096:biosynthesis
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D014640:Vancomycin; D000078304:Tigecycline; D001618:beta-Lactamases; D008911:Minocycline